Global asset manager Fidelity International invested $5.2 million in Cynata Therapeutics, an Australian stem cell and regenerative medicine company, Business Insider Australia reports.
Biologics
The global spine biologics market is forecasted to grow at a compound annual growth rate of 4.09 percent between 2018 and 2022, according to a Technavio report.
DiscGenics principal investigator Domagoj Coric, MD, of Carolina Neurosurgery and Spine Associates in Charlotte, N.C., treated the first patient in the phase 1/phase 2 clinical trial of IDCT.
Organogenesis is a regenerative medicine company based in Canton, Mass., focused on developing products for the wound care, surgical and sports medicine markets.
Treating knee arthritis with NASHA (durolane hyaluronic acid) is a safe and effective procedure, according to a study in Open Access Rheumatology: Research and Reviews.
Advertisement
Here are the 14 major players in the global spine biologics market, according to an E Market Research report.
Mikkel O. Andersen, MD, of Middelfart Hospital in Denmark, reported results from the IVANOS study investigating Cerapedics' i-FACTOR Peptide Enhanced Bone Graft.
Burst Biologics, based in Boise, Idaho, is a regenerative medicine company.
Orthopedic surgeons continue to express concerns over various stem cell treatments being offered to patients, according to Contact7.
Insurers will not usually pay for unproven stem cell treatments, so patients seeking those interventions must pay out-of-pocket or use social media to receive donations, a practice known as crowdfunding. Medical crowdfunding campaigns may convey misleading messages about stem cell-based…